6-K filed Aug 4, 2026 at 07:59 ET
Fresenius Medical Care reported mixed Q2 2026 results. Revenue grew 1% as-reported (4% constant currency) to €4.86B, and operating income rose 10% to €466M, driven by Care Delivery and cost savings from the FME25+ program. However, net income attributable to shareholders declined 3% to €218M, dragged by a €71M negative impact from the TAVNEOS marketing authorization revocation at its VFMCRP equity method investee. U.S. same-market treatment growth was negative (-0.9%), and the company faces headwinds from the OBBBA legislation and the expected reversal of TDAPA reimbursement benefits in H2 2026. The filing also details a new €1B share buyback program launched in May 2026, with €600M first tranche underway.